Skip to main content

Advertisement

SpringerLink
Log in

CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor‐specific therapies

  • Review
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Abdominal manifestations in patients with cutaneous melanoma include involvement due to metastatic spread and immune checkpoint inhibitor induced adverse events. The purpose of this review is to provide a critical overview of abdominal manifestations in patients with cutaneous melanoma and highlight the current imaging challenges in the era of tumor‐specific therapies. Immune checkpoint inhibitors represent a treatment with demonstrated efficacy in the treatment of advanced cutaneous melanoma but are associated with several abdominal adverse events that must be recognized. CT has a role in the identification of colitis, enteritis and pancreatitis, whereas MRI has an important role in the diagnosis of autoimmune pancreatitis. Current evidence demonstrates that MRI should be the preferred imaging technique for the detection and characterization of hepatic and splenic metastases from cutaneous melanoma. The role of 18F-FDG-PET/CT should be further evaluated but current literature suggests an efficacy in the detection of pancreatic metastases not seen on CT and MRI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14

Similar content being viewed by others

Abbreviations

18FDG:

18 fluorodeoxyglucose

AIP:

Autoimmune pancreatitis

AJCC:

American Joint Committee on Cancer

CT:

Computed tomography

CTLA-4:

Cytotoxic T-lymphocyte-associated antigen-4

IRAE:

Immune-related adverse event

irRC:

Immune-related response criteria

MAPK:

Mitogen‐activated protein kinase

MRI:

Magnetic resonance imaging

PD-1:

Programmed-death-1

PET:

Positron emission tomography

RECIST:

Response evaluation criteria in solid tumors

VCE:

Videocapsule endoscopy

References

  1. Carr S, Smith C, Wernberg J. Epidemiology and Risk Factors of Melanoma. Surg Clin North Am 2020;100(1):1–12.

    PubMed  Google Scholar 

  2. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 2014;28(6):1005–1011.

    Google Scholar 

  3. Pasquali S, Haydu LE, Scolyer RA, Winstanley JB, Spillane AJ, Quinn MJ, et al. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. Ann Surg 2013;258(1):152–157.

    PubMed  Google Scholar 

  4. Duncan LM. The classification of cutaneous melanoma. Hematol Oncol Clin North Am 2009;23(3):501–513.

    PubMed  Google Scholar 

  5. Benaissa A, Fornès P, Ladam-Marcus V, Grange F, Amzallag-Bellenger E, Hoeffel C. Multimodality imaging of melanoma metastases to the abdomen and pelvis. Clin Imaging 2011;35(6):452–458.

    PubMed  Google Scholar 

  6. Chang ST, Desser TS, Gayer G, Menias CO. Metastatic melanoma in the chest and abdomen: the great radiologic imitator. Semin Ultrasound CT MR 2014;35(3):272–289.

    PubMed  Google Scholar 

  7. Patnana M, Bronstein Y, Szklaruk J, Bedi DG, Hwu WJ, Gershenwald JE, et al. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 2011;66(3):224–236.

    CAS  PubMed  Google Scholar 

  8. Dancey AL, Mahon BS, Rayatt SS. A review of diagnostic imaging in melanoma. J Plast Reconstr Aesthet Surg 2008;61(11):1275–1283.

    CAS  PubMed  Google Scholar 

  9. King DM. Imaging of metastatic melanoma. Cancer Imaging 2006;6:204-208.

    PubMed  Google Scholar 

  10. Mocellin S, Nitti D. CTLA‐4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta 2013;1836(2):187–196.

    CAS  PubMed  Google Scholar 

  11. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003;22:3087–3091.

    CAS  PubMed  Google Scholar 

  12. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29(10):1239–1246.

    PubMed  Google Scholar 

  13. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161(7):1681–96

    Google Scholar 

  14. Pasquali S, Chiarion-Sileni V, Rossi CR, Mocellin S. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: a network meta-analysis. Cancer Treat Rev 2017;54:34–42.

    CAS  PubMed  Google Scholar 

  15. Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, et al. Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade. Ann Surg Oncol 2019;27(4):1180–1188.

    PubMed  PubMed Central  Google Scholar 

  16. Larkin J, Vanna Chiarion-Sileni V, Gonzalez R, Grob JJ, Lance Cowey C, Lao CD et al. Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med 2015;373(1):23–34.

    PubMed  PubMed Central  Google Scholar 

  17. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372(26):2521–2532.

    CAS  PubMed  Google Scholar 

  18. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, et al. Melanoma immunotherapy. Cancer Biol Ther 2014;15(6):665e74.

    PubMed  PubMed Central  Google Scholar 

  19. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378(2):158e68.

    CAS  PubMed  Google Scholar 

  20. Laurent V, Trausch G, Bruot O, Olivier P, Felblinger J, Régent D. Comparative study of two whole body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PETCT. Eur J Radiol 2009;75:376–383.

    PubMed  Google Scholar 

  21. Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43(3):557–564.

    PubMed  Google Scholar 

  22. Muller-Horvat C, Radny P, Eigentler TK, Schäfer J, Pfannenberg C, Horger M, et al. Prospective comparison of the impact on treatment decisions of whole body MRI and CT in patients with metastatic malignant melanoma. Eur J Cancer 2006;42(3):342–343.

    PubMed  Google Scholar 

  23. Uhrig M, Simons D, Bonekamp D, Schlemmer HP. Improved detection of melanoma metastases by iodine maps from dual energy CT. Eur J Radiol 2017;90:27–33.

    PubMed  Google Scholar 

  24. Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: MRI. Cancer Imaging 2007;7(1):2–9.

    PubMed  PubMed Central  Google Scholar 

  25. Keraliya AR, Krajewski KM, Braschi-Amirfarzan M, Tirumani SH, Shinagare AB, Jagannathan JP, et al. Extracutaneous melanomas: a primer for the radiologist. Insights Imaging 2015;6(6):707–717.

    PubMed  PubMed Central  Google Scholar 

  26. Wagner M, Mariani P, Bidard FC, Rodrigues MJ, Farkhondeh F, Cassoux N, et al. Diffusion-weighted MRI for uveal melanoma liver metastasis detection. Eur Radiol 2015;25(8):2263–2273.

    PubMed  Google Scholar 

  27. Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol 2005;40(12):743–753.

    PubMed  Google Scholar 

  28. Sofue K, Tateishi U, Tsurusaki M, Arai Y, Yamazaki N, Sugimura K. MR imaging of hepatic metastasis in patients with malignant melanoma: evaluation of suspected lesions screened at contrast-enhanced CT. Eur J Radiol 2012;81(4):714–748.

    PubMed  Google Scholar 

  29. Ghanem N, Altehoefer C, Högerle S, Nitzsche E, Lohrmann C, Schäfer O, et al. Detectability of liver metastases in malignant melanoma: prospective comparison of magnetic resonance imaging and positron emission tomography. Eur J Radiol 2005;54(2):264–270.

    PubMed  Google Scholar 

  30. Schröer-Günther MA, Wolff RF, Westwood ME, Scheibler FJ, Schürmann C, Baumert BG, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev 2012;1:62.

    PubMed  PubMed Central  Google Scholar 

  31. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009;27(28):4774–4780.

    PubMed  Google Scholar 

  32. Durot C, Mulé S, Soyer P, Marchal A, Grange F, Hoeffel C. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab. Eur Radiol 2019;29(6):3183–3191.

    PubMed  Google Scholar 

  33. Schraag A, Klumpp B, Afat S, Gatidis S, Nikolaou K, Eigentler TK, et al. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy. Eur J Radiol 2019;121:108688.

    PubMed  Google Scholar 

  34. Backman H. Metastasis of malignant melanoma in the gastrointestinal tract. Geriatrics 1999;24(8):112–120.

    Google Scholar 

  35. Das Gupta T, Brasfield RD. Metastatic melanoma to the gastrointestinal tract. Arch Surg 1964;88:969–973.

    CAS  Google Scholar 

  36. Antonini F, Acito L, Sisti S, Angelelli L, Macarri G. Metastatic melanoma of the gallbladder diagnosed by EUS-guided FNA. Gastrointest Endosc 2016;84(6):1072–1073.

    PubMed  Google Scholar 

  37. Dong XD, DeMatos P, Prieto VG, Seigler HF. Melanoma of the gallbladder: a review of cases seen at Duke University Medical Center. Cancer 1999;85(1):32–39.

    CAS  PubMed  Google Scholar 

  38. Medina V, Darnell A, Bejarano N, Falcó J, Musulen E, Martin J. Primary biliary tract malignant melanoma: US, CT, and MR findings. Abdom Imaging 2003;28(6):842–846.

    CAS  PubMed  Google Scholar 

  39. Guida M, Cramarossa A, Gentile A, Benvestito S, De Fazio M, Sanbiasi D, et al. Metastatic malignant melanoma of the gallbladder: a case report and review of the literature. Melanoma Res 2002;12(6):619–625.

    CAS  PubMed  Google Scholar 

  40. Rehani B, Strohmeyer P, Jacobs M, Mantil J. Gallbladder metastasis from malignant melanoma: diagnosis with FDG PET/CT. Clin Nucl Med 2006;31(12):812–823.

    PubMed  Google Scholar 

  41. O’Connell JB, Whittemore DM, Russell JC, Ellis WA, Becker DR. Malignant melanoma metastatic to the cystic duct and common bile ducts. Cancer 1984;53(1):184–186.

    PubMed  Google Scholar 

  42. Wagner MS, Shoup M, Pickleman J, Yong S. Primary malignant melanoma of the common bile duct: a case report and review of the literature. Arch Pathol Lab Med 2000;124(3):419–422.

    CAS  PubMed  Google Scholar 

  43. Garas G, Bramston B, Edmunds SE. Malignant melanoma metastatic to the common bile duct. J Gastroenterol Hepatol 2000;15(11):1348–1351.

    CAS  PubMed  Google Scholar 

  44. Reintgen DS, Thompson W, Garbutt J, Seigler HF Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery 1984;95(6):635–639.

    CAS  PubMed  Google Scholar 

  45. Albert JG, Fechner M, Fiedler E, Voderholzer W, Lochs H, Trefzer U, et al. Algorithm for detection of small-bowel metastasis in malignant melanoma of the skin. Endoscopy 2011;43(6):490–498.

    CAS  PubMed  Google Scholar 

  46. Tsilimparis N, Menenakos C, Rogalla P, Braumann C, Hartmann J. Malignant melanoma metastasis as a cause of small-bowel perforation. Onkologie 2009;32(6):356–358.

    PubMed  Google Scholar 

  47. Butte JM, Meneses M, Waugh E, Parada H, De La Fuente H. Ileal intussusception secondary to small bowel metastases from melanoma. Am J Surg 2009;198(1):e1–e2.

    PubMed  Google Scholar 

  48. Bender GN, Maglinte DD, McLarney JH, Rex D, Kelvin FM. Malignant melanoma: patterns of metastasis to the small bowel, reliability of imaging studies, and clinical relevance. Am J Gastroenterol 2001;96(8):2392–2400.

    CAS  PubMed  Google Scholar 

  49. Panagiotou I, Brountzos EN, Bafaloukos D, Stoupis C, Brestas P, Kelekis DA. Malignant melanoma metastatic to the gastrointestinal tract. Melanoma Res 2002;12(2):169–173.

    CAS  PubMed  Google Scholar 

  50. Crippa S, Bovo G, Romano F, Mussi C, Uggeri F. Melanoma metastatic to the gallbladder and small bowel: report of a case and review of the literature. Melanoma Res 2004;14(5):427–430.

    PubMed  Google Scholar 

  51. Mucci T, Long W, Witkiewicz A, Mastrangelo MJ, Rosato EL, Berger AC. Metastatic melanoma causing jejunal intussusception. J Gastrointest Surg 2007;11(12):1755–1757.

    PubMed  Google Scholar 

  52. Othman AE, Eigentler TK, Bier G, Pfannenberg C, Bösmüller H, Thiel C, et al. Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen. Eur Radiol 2017;27(6):2538–2545.

    PubMed  Google Scholar 

  53. Lens M, Bataille V, Krivokapic Z. Melanoma of the small intestine. Lancet Oncol 2009;10(5):516–521.

    PubMed  Google Scholar 

  54. Prakoso E, Selby WS. Capsule endoscopy in patients with malignant melanoma. Am J Gastroenterol 2007;102(6):1204–1208.

    PubMed  Google Scholar 

  55. Prakoso E, Fulham M, Thompson JF, Selby WS. Capsule endoscopy versus positron emission tomography for detection of small-bowel metastatic melanoma: a pilot study. Gastrointest Endosc 2011;73(4):750–756.

    PubMed  Google Scholar 

  56. Khalife S, Soyer P, Alatawi A, Vahedi K, Hamzi L, Dray X, et al. Obscure gastrointestinal bleeding: preliminary comparison of 64-section CT enteroclysis with video capsule endoscopy. Eur Radiol 2011;21(1):79-86.

    PubMed  Google Scholar 

  57. Soyer P, Aout M, Hoeffel C, Vicaut E, Placé V, Boudiaf M. Helical CT-enteroclysis in the detection of small-bowel tumours: a meta-analysis. Eur Radiol 2013;23(2):388–399.

    PubMed  Google Scholar 

  58. Soyer P, Boudiaf M, Fishman EK, Hoeffel C, Dray X, Manfredi R, et al. Imaging of malignant neoplasms of the mesenteric small bowel: new trends and perspectives. Crit Rev Oncol Hematol 2011;80(1):10–30.

    PubMed  Google Scholar 

  59. Liang KV, Sanderson SO, Nowakowski GS, Arora AS. Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc 2006;81(4):511–516.

    PubMed  Google Scholar 

  60. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma: a study of 216 autopsy cases. Am J Surg 1978;135(6):807–810.

    CAS  PubMed  Google Scholar 

  61. Michalinos A, Felekouras E, Athanasiou A, Tsaparas P, Mantas D, Kouraklis G. Melanoma metastases to gastrointestinal tract. Am Surg 2015;81(5):E212–214.

    PubMed  Google Scholar 

  62. Wang J, Ao WQ, Liu C, Zhang WM, Xu FY. Primary gastric melanoma: a case report with imaging findings and 5-year follow-up. World J Gastroenterol 2019; 25(44): 6571–6578.

    PubMed  PubMed Central  Google Scholar 

  63. Tessier DJ, McConnell EJ, Young-Fadok T, Wolff BG. Melanoma metastatic to the colon: case series and review of the literature with outcome analysis. Dis Colon Rectum 2003;46(4):441–447.

    PubMed  Google Scholar 

  64. Eloubeidi MA, Gaede JT, Davis WZ. Isolated metastatic melanoma to the colon mimicking colon cancer. Gastrointest Endosc 2000;52(6):751–752.

    CAS  PubMed  Google Scholar 

  65. Park JS, Ng KS, Saw RPM, Thompson JF, Young CJ. Metastatic melanoma to the colon, rectum, and anus: a 50-year experience. Ann Surg Oncol 2018;25(8):2178–2183.

    PubMed  Google Scholar 

  66. Watson RGK, McMullin JP. Intussusception of the colon secondary to gastrointestinal metastatic melanoma. J R Coll Surg Edinb 1980;25(3):200–201.

    CAS  PubMed  Google Scholar 

  67. Grignon DJ, Ro JY, Varona OB, et al. Malignant melanoma with metastasis to a colonic polyp. Am J Gastroenterol 1988; 83(11):1298–1300.

    CAS  PubMed  Google Scholar 

  68. McClenathan JH. Metastatic melanoma involving the colon. Dis Col Rectum 1989;32(31):70–72.

    CAS  Google Scholar 

  69. Galloro G, Inzirillo A, Magno L, Diamantis G, Inzirillo M, Pastore A, et al. Multiple nodular lesions by colonic metastatic malignant melanoma. Dig Liver Dis 2009;41(2):169.

    CAS  PubMed  Google Scholar 

  70. Kinner S, Lauenstein TC. MR colonography. Radiol Clin North Am 2007;45(2):377–387.

    PubMed  Google Scholar 

  71. Untch BR, Allen PJ. Pancreatic metastasectomy: the Memorial Sloan-Kettering experience and a review of the literature. J Surg Oncol 2014;109(1):28–30.

    PubMed  Google Scholar 

  72. Barral M, Faraoun SA, Fishman EK, Dohan A, Pozzessere C, Berthelin MA, et al. Imaging features of rare pancreatic tumors. Diagn Interv Imaging 2016;97(12):1259–1273.

    CAS  PubMed  Google Scholar 

  73. Sperti C, Polizzi ML, beltrame V, Moro M, Pedrazzoli S. Pancreatic resection for metastatic melanoma: case report and review of the literature. J Gastrointest Cancer 2011;42(4):302–306.

    PubMed  Google Scholar 

  74. Brodish RJ, McFadden DW. The pancreas as the solitary site of metastasis from melanoma. Pancreas 1993;8(2):276–278.

    CAS  PubMed  Google Scholar 

  75. Pang JC, Roh MH. Metastases to the pancreas encountered on endoscopic ultrasound-guided fine-needle aspiration. Arch Pathol Lab Med 2015;139(10):1248–1252.

    PubMed  Google Scholar 

  76. DeWitt JM, Chappo J, Sherman S. Endoscopic ultrasound-guided fine-needle aspiration of melanoma metastatic to the pancreas: report of two cases and review. Endoscopy 2003;35(3):219–222.

    CAS  PubMed  Google Scholar 

  77. Wood TF, DiFronzo LA, Rose DM, Haigh PI, Stern SL, Wanek L, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 2001;8(8):658–662.

    CAS  PubMed  Google Scholar 

  78. Scatarige JC, Horton KM, Sheth S, Fishman EK. Pancreatic parenchymal metastases: observations on helical CT. AJR Am J Roentgenol 2001;176(3):695–699.

    CAS  PubMed  Google Scholar 

  79. Jana T, Caraway NP, Irisawa A, Manoop S, Bhutani MS. Multiple pancreatic metastases from malignant melanoma: Conclusive diagnosis with endoscopic ultrasound-guided fine needle aspiration. Endosc Ultrasound 2015;4(2):145–148.

    PubMed  PubMed Central  Google Scholar 

  80. Merkle EM, Boaz T, Kolokythas O, Haaga JR, Lewin JS, Brambs HJ. Metastases to the pancreas. Br J Radiol 1998;71(851):1208–1214.

    CAS  PubMed  Google Scholar 

  81. Klein KA, Stephens DH, Welch TJ. CT characteristics of metastatic disease of the pancreas. Radiographics 1998;18(2):369–378

    CAS  PubMed  Google Scholar 

  82. Nakamura Y, Yamada R, Kaneko M, Naota H, Fujimura Y, Tabata M, et al. Isolated pancreatic metastasis from malignant melanoma: a case report and literature review. Clin J Gastroenterol 2019;12(6):626–636.

    PubMed  PubMed Central  Google Scholar 

  83. Nikfarjam M, Evans P, Christophi C. Pancreatic resection for metastatic melanoma. HPB 2003;5(3):174–179.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Shirkhoda A, Albin J. Malignant melanoma: correlating abdominal and pelvic CT with clinical staging. Radiology 1987;165(1):75–78.

    CAS  PubMed  Google Scholar 

  85. Das Gupta T, Brasfield R. Metastatic melanoma: a clinic pathological study. Cancer 1964;17:1323–1339.

    CAS  Google Scholar 

  86. Badet N, Sailley N, Briquez C, Paquette B, Vuitton L, Delabrousse É. Mesenteric panniculitis: still an ambiguous condition. Diagn Interv Imaging 2015;96(3):251–257.

    CAS  PubMed  Google Scholar 

  87. Protin-Catteau L, Thiéfin G, Barbe C, Jolly D, Soyer P, Hoeffel C. Mesenteric panniculitis: review of consecutive abdominal MDCT examinations with a matched-pair analysis. Acta Radiol 2016;57(12):1438–1444.

    PubMed  Google Scholar 

  88. Soyer P, Hoeffel C, Zins M. Mesenteric panniculitis: more research is needed. Diagn Interv Imaging 2015;96(3):225-256.

    CAS  PubMed  Google Scholar 

  89. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016;22(4):886–894.

    CAS  PubMed  Google Scholar 

  90. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2015;3(10):1185–1192.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563–580.

    CAS  PubMed  Google Scholar 

  93. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti–CTLA-4 antibody therapy. AJR Am J Roentgenol 2011;197(6):W992–W1000.

    PubMed  Google Scholar 

  94. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Supplement 4):iv264–iv266.

  95. Thornton E, Howard SA, Jagannathan J, Krajewski KM, Shinagare AB, O’Regan K, et al. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol 2012;85(1018):1420–1426.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, et al. Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients. Cancer Immunol Res 2017;5(4):286–291.

    CAS  PubMed  Google Scholar 

  97. Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, et al. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol 2019;44:1917–1927.

    Google Scholar 

  98. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018;4(2):173–182.

    PubMed  Google Scholar 

  99. Graziani R, Mautone S, Ambrosetti MC, Manfredi R, Re TJ, Calculli L, et al. Autoimmune pancreatitis: multidetector-row computed tomography (MDCT) and magnetic resonance (MR) findings in the Italian experience. Radiol Med 2014;119(8):558–571.

    PubMed  Google Scholar 

  100. Dehghani L, Mikail N, Kramkimel N, Soyer P, Lebtahi R, Mallone R, et al. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment. Eur J Cancer 2018;104:243–246.

    CAS  PubMed  Google Scholar 

  101. Fan RY, Sheng JQ. Immunoglobulin G4-related autoimmune pancreatitis and sialadenitis: a case report. World J Gastroenterol 2015;21(31):9448-9452.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Tanaka T, Sakai A, Kobayashi T, Masuda A, Shiomi H, Kodama Y. Nivolumab-related pancreatitis with autoimmune pancreatitis-like imaging features. J Gastroenterol Hepatol 2019;34(8):1274.

    CAS  PubMed  Google Scholar 

  103. Park S, Chu LC, Hruban RH, Vogelstein B, Kinzler KW, Yuille AL, et al. Differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma with CT radiomics features. Diagn Interv Imaging 2020;101(9):555–564.

    CAS  PubMed  Google Scholar 

  104. Marchand L, Thivolet A, Saintigny P, Fabien N, Vouillarmet J, Thivolet C. Antiprogrammed death 1 (PD-1) antibodies and the pancreas: a diabetic storm ahead? Diabetes Care 2018;41(3):638e9.

  105. Rawson RV, Robbins E, Kapoor R, Scolyer RA, Long GV. Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. Eur J Cancer 2017;82:167–170.

    PubMed  Google Scholar 

  106. Raad RA, Pavlick A, Kannan R, Friedman KP. Ipilimumab-induced hepatitis on 18FFDG PET/CT in a patient with malignant melanoma. Clin Nucl Med 2015;40(3):258e9

    PubMed  Google Scholar 

  107. Wartski M, Sauvanet A. 18F-FDG PET/CT in pancreatic adenocarcinoma: a role at initial imaging staging? Diagn Interv Imaging 2019;100(12):735–741.

    CAS  PubMed  Google Scholar 

  108. Alabed YZ, Aghayev A, Sakellis C, Van den Abbeele AD. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin Nucl Med 2015;40(11):e528e9.

  109. Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, et al. Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study. Cancer Immunol Res 2018;6(12):1453–1458.

    CAS  PubMed  Google Scholar 

  110. Wang GX, Kurra V, Gainor JF, Sullivan RJ, Flaherty KT, Lee SI, et al. Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics 2017;37(7):2132–2144.

    PubMed  Google Scholar 

  111. Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol 2018;41(8):760–765.

    CAS  PubMed  Google Scholar 

  112. Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013;31(4):1071–1077.

    CAS  PubMed  Google Scholar 

  113. Charvet E, Lheure C, Isnard C, Franck N, Kramkimel N, Vallet-Pichard A, et al. Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report. Ann Oncol 2020; https://doi.org/10.1016/j.annonc.2020.02.004.

    Article  PubMed  Google Scholar 

  114. Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 2017;8:730

    PubMed  PubMed Central  Google Scholar 

  115. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15(23):7412–7420.

    CAS  PubMed  Google Scholar 

  116. Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, et al. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol 2017;120:13–21.

    PubMed  Google Scholar 

  117. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunothera-peutics. Lancet Oncol 2017;18(3):e143–e152.

    PubMed  PubMed Central  Google Scholar 

  118. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015;13:211.

    PubMed  PubMed Central  Google Scholar 

  119. Beregi JP, Greffier J. Low and ultra-low dose radiation in CT: opportunities and limitations. Diagn Interv Imaging 2019;100(2):63-64

    CAS  PubMed  Google Scholar 

Download references

Funding

This study did not receive specific funding.

Author information

Authors and Affiliations

  1. Department of Abdominal & Interventional Radiology, Hôpital Cochin, AP-HP, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France

    Maxime Barat, Enora Guillo, Anthony Dohan & Philippe Soyer

  2. Université de Paris, Descartes-Paris 5, rue de l’Ecole de Médecine, F-75006, Paris, France

    Maxime Barat, Sarah Guegan-Bart, Anne-Ségolène Cottereau, Maximilien Barret, Sébastien Gaujoux, Anthony Dohan & Philippe Soyer

  3. Department of Dermatology, Hôpital Cochin, AP-HP, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France

    Sarah Guegan-Bart

  4. Department of Nuclear Medicine, Hôpital Cochin, AP-HP, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France

    Anne-Ségolène Cottereau

  5. Department of Radiology, Hôpital Robert Debré, 11 Boulevard Pasteur, 51092, Reims, France

    Christine Hoeffel

  6. Department of Gastroenterology, Hôpital Cochin, AP-HP, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France

    Maximilien Barret

  7. Department of Abdominal Surgery, Hôpital Cochin, AP-HP, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France

    Sébastien Gaujoux

Authors
  1. Maxime Barat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah Guegan-Bart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne-Ségolène Cottereau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enora Guillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christine Hoeffel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maximilien Barret
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sébastien Gaujoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anthony Dohan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Philippe Soyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Guarantor of integrity of the entire study: PS. Study concepts and design: MB, EG, SGB, PS. Literature research: MB, EG, SGB, ASC, CH, MB, SG, AD, PS. Clinical studies: MB, EG, SGB, ASC, CH, MB, SG, AD, PS. Experimental studies/data analysis: N.A. Statistical analysis: N.A. Manuscript preparation: MB, EG, SGB, ASC, CH, MB, SG, AD, PS. Manuscript editing: MB, EG, SGB, ASC, CH, MB, SG, AD, PS. All authors attest that they meet the current International Committee of Medical Journal Editors (ICMJE) criteria for Authorship.

Corresponding author

Correspondence to Philippe Soyer.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interest or personal relationships that could have appeared to influence the work reported in this paper.

Informed consent

The authors declare that this report does not contain any personal information that could lead to the identification of the patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barat, M., Guegan-Bart, S., Cottereau, AS. et al. CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor‐specific therapies. Abdom Radiol 46, 2219–2235 (2021). https://doi.org/10.1007/s00261-020-02837-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-020-02837-4

Keywords

Search

Navigation